The Pandemic Promised a Vaccine Boom. Valneva Just Hit the Wall.

The Lyme Disease Bet That Could Flip the Script

Beneath all the travel vaccine noise, Valneva has a card up its sleeve: VLA15, a Lyme disease vaccine developed in partnership with Pfizer. It's the only late-stage Lyme vaccine program in the world. Phase 3 data is expected in the first half of 2026.

If it works, this could be transformational. Lyme disease affects hundreds of thousands of people annually in the U.S. and Europe, and there hasn't been a vaccine on the market since LYMErix was pulled in 2002. The commercial opportunity dwarfs travel vaccines.

But "if" is doing a lot of heavy lifting in that sentence. Goldman Sachs currently has a Sell rating on Valneva with a price target of just €2.15, citing concerns about dilution and clinical risk.

The restructuring, then, is partly about surviving long enough to find out whether VLA15 delivers. Valneva raised €84 million through a private placement in early May (€37 million upfront, with another €47 million contingent on FDA approval of the Lyme vaccine). That buys time, but it also dilutes existing shareholders.

Valneva Isn't Alone in the Pain

This isn't just a Valneva story. It's a sector-wide correction.

Bavarian Nordic, the Danish company behind the mpox vaccine Jynneos, shut down its San Diego R&D site in early 2025, laying off all 48 employees. Novavax cut roughly 25% of its workforce in 2023. Moderna trimmed about 10% of its workforce in 2025. Even with a global travel vaccine market growing at nearly 10% annually, specialty vaccine companies are being forced to right-size after pandemic-era optimism inflated their headcounts and spending.

The pattern is clear: companies that rode the COVID wave into broader vaccine ambitions are now discovering that pre-pandemic economics still apply. Revenue doesn't grow in a straight line. Clinical programs fail. And investors who once threw money at anything with "vaccine" in the pitch deck have gotten pickier.

The Math Behind Survival

Valneva's restructuring plan, launched in April 2026, builds on earlier moves. The company already closed its Nantes, France facility (cutting about 30 positions) and consolidated production in Lyon. The new cuts go deeper, targeting the organizational chart itself rather than individual sites.

The financial logic is straightforward. In 2025, Valneva reduced its operating cash burn by 21%. Now it's aiming for that 25-35% cut in operating expenses. If the company hits those targets while maintaining its core vaccine sales (IXIRO for Japanese encephalitis, DUKORAL for cholera), it can stretch its runway to the Lyme data readout and potentially beyond.

What to Watch

Three things will determine whether Valneva's restructuring is a smart pivot or just a slower bleed:

1. VLA15 Phase 3 data (H1 2026). This is the whole ballgame. A positive readout with Pfizer's marketing muscle behind it would rewrite Valneva's story overnight.

2. IXCHIQ commercial traction. The chikungunya vaccine showed strong four-year antibody persistence data, and a pilot campaign in Brazil (with Instituto Butantan) could open emerging markets. But without clearer regulatory pathways outside the U.S., uptake may remain disappointing.

3. Cash management. At €110 million plus the new raise, Valneva has enough runway if it executes on cost cuts. But biotech companies rarely get second chances at the fundraising window. Every quarter of cash burn matters.

The travel vaccine boom didn't die. It just didn't arrive as fast as some companies needed it to. For Valneva, the question is whether it can trim enough fat to stay alive until its real moonshot, Lyme disease, either makes or breaks the company. The next six months will tell us everything.

Pfizer Just Crashed the Hardest Party in Hemophilia

Pfizer just won EU approval to treat the hardest cases in hemophilia: patients whose immune systems attack their own medication. The Phase 3 data showed a 93% drop in bleeding, and the competitive implications are fascinating.